Respiratory distress syndrome therapy with peptide analogs of human SP-B
AssigneeHarbor-UCLA Research and Education Institute
InventorsFrans J. Walther, Alan J. Waring, Larry M. Gordon, Joseph A. Zasadzinski
Life of this patent
Estimating the term…
Abstract
A therapeutic pharmaceutical composition for the treatment of respiratory disease is disclosed, including particularly Respiratory Distress Syndrome (RDS). The composition is comprised of a synthetic dimer of an N-terminal fragment of Surfactant Protein B (SP-B) that advantageously mimics the functional activity of native human Surfactant Protein B, and to therapeutic methods of administration of such pharmaceutical compositions.
Claims8
A peptide analog of lung surfactant protein B comprising:
- a dimer of a synthetic peptide consisting of amino acid residues 1-25 of SEQ ID NO:
- 2.
A peptide analog of lung surfactant protein B comprising:
- a dimer of a synthetic peptide consisting of amino acid residues 1-25 of SEQ ID NO:
- 3.
A pharmaceutical composition comprising:
- a peptide analog of lung surfactant protein B comprising a dimer of a synthetic peptide consisting of amino acid residues 1-25 of SEQ ID NO:
- 2;
- and
- an animal derived lung surfactant comprised of natural lung surfactant proteins.
A pharmaceutical composition comprising:
- a peptide analog of lung surfactant protein B comprising a dimer of a synthetic peptide consisting of amino acid residues 1-25 of SEQ ID NO:
- 3;
- and
- an animal derived lung surfactant comprised of natural lung surfactant proteins.
A dimer peptide analog of mammalian lung surfactant protein B comprising monomer peptides consisting of SEQ ID NO:
- 2 having a Cys 8 to Cys8 disulfide link, wherein the monomer peptides contain an amphipathic α-helical domain.
Dependencies are inferred from the claim text.